TransMedics Group, Inc. (TMDX) Return on equity 2019–2025
TransMedics Group, Inc. (TMDX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
40.2%FY2025 · since FY2019: -61.4% → 40.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 40.2% | +24.7 pp |
| FY2024 | 15.5% | +33.8 pp |
| FY2023 | -18.2% | +1.1 pp |
| FY2022 | -19.3% | +45.8 pp |
| FY2021 | -65.1% | -37.5 pp |
| FY2020 | -27.7% | +33.7 pp |
| FY2019 | -61.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice